Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease
Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with radiation therapy alone in treating patients with early-stage Hodgkin's disease.
研究概览
详细说明
OBJECTIVES: I. Determine the recurrence rate and long term survival of patients with early stage Hodgkin's disease given vincristine/doxorubicin/prednisolone/ etoposide/cyclophosphamide/bleomycin (VAPEC-B) chemotherapy and involved field radiation vs mantle radiotherapy.
OUTLINE: This is a randomized multicenter study. Patients are randomized to receive either vincristine/doxorubicin/prednisolone/etoposide/cyclophosphamide/ bleomycin (VAPEC-B) chemotherapy and involved field radiotherapy or mantle radiotherapy only. Patients receiving VAPEC-B are given prednisolone daily on weeks 1-6, doxorubicin IV along with cyclophosphamide IV on week 1, doxorubicin IV and etoposide orally for 5 days on week 3, and vincristine and bleomycin IV on weeks 2 and 4. Involved field radiotherapy is commenced at week 6, within 14 to 21 days of the last chemotherapy treatment. Patients randomized to receive mantle radiotherapy only are given treatments daily for 4 weeks. Patients are followed every 3 months for the first two years, every 4 months for the third year, every 6 months for the fourth and fifth years and annually thereafter.
PROJECTED ACCRUAL: 400 patients will be accrued over 4-5 years.
研究类型
注册 (预期的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Cape Town、南非、7925
- Groote Schuur Hospital, Cape Town
-
-
-
-
-
Preston、英国、PR2 9HT
- Royal Preston Hospital
-
-
England
-
Birmingham、England、英国、B15 2TT
- University Birmingham
-
Bristol、England、英国、BS2 8ED
- Bristol Oncology Centre
-
Bristol、England、英国、BS2 8BJ
- Bristol Royal Hospital for Sick Children
-
Cambridge、England、英国、CB2 2QQ
- Addenbrooke's NHS Trust
-
Derby、England、英国、DE1 2QY
- Derbyshire Royal Infirmary
-
Leeds、England、英国、LS16 6QB
- Cookridge Hospital
-
Leicester、England、英国、LE1 5WW
- University Hospitals of Leicester
-
London、England、英国、W1G 3AA
- Middlesex Hospital- Meyerstein Institute
-
Merseyside、England、英国、L63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne、England、英国、NE4 6BE
- Newcastle General Hospital
-
Northwood、England、英国、HA6 2RN
- Mount Vernon Hospital
-
Norwich、England、英国、NR1 3SR
- Norfolk & Norwich Hospital
-
Oxford、England、英国、0X3 9DU
- Oxford Radcliffe Hospital
-
Sutton、England、英国、SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea、England、英国
- Southend General Hospital
-
-
Scotland
-
Edinburgh、Scotland、英国
- Royal Hospital for Sick Children
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS: Histologically proven stage IA or IIA Hodgkin's disease without mediastinal bulk Patients with Hodgkin's disease existing below diaphragm only are not eligible
PATIENT CHARACTERISTICS: Age: 16 to 75 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not HIV positive No prior malignancy other than basal cell carcinoma or cervical intraepithelial neoplasia
PRIOR CONCURRENT THERAPY: No prior treatment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
调查人员
- 学习椅:Michael Williams, MD、Cambridge University Hospitals NHS Foundation Trust
出版物和有用的链接
一般刊物
- Radford JA, Williams MV, Hancock BW, et al.: Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial. [Abstract] Eur J Haematol 73 (Suppl 65): A-E08, 39, 2004.
研究记录日期
研究主要日期
学习开始
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CDR0000065522
- MRC-UKLG-LY07
- EU-97004
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.